Polypill comprising aspirin, ramipril, atorvastatin effective for secondary prevention of cardiovascular disease in older adults<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
\n\tTUESDAY, Aug. 30, 2022 (HealthDay News) — The risk for major adverse cardiovascular events is reduced among patients within six months of previous myocardial infarction who receive treatment with a polypill compared with usual care, according to a study published online Aug. 26 in the New England Journal of Medicine<\/em> to coincide with the European Society of Cardiology Congress 2022, held from Aug. 26 to 29 in Barcelona, Spain.\n<\/p>\n \n\tJose M. Castellano, M.D., Ph.D., from Centro Nacional de Investigaciones Cardiovasculares in Madrid, and colleagues conducted a phase 3 randomized trial involving patients with myocardial infarction within the previous six months who were randomly assigned to either a polypill-based strategy, consisting of aspirin, ramipril, and atorvastatin, or usual care. A total of 2,499 patients were randomly assigned and followed for a median of 36 months.\n<\/p>\n \n\tThe researchers found that a primary outcome event (cardiovascular death, nonfatal type 1 myocardial infarction, nonfatal ischemic stroke, or urgent revascularization) occurred in 9.5 percent of 1,237 patients in the polypill group and in 12.7 percent of 1,229 patients in the usual-care group (hazard ratio, 0.76). A key secondary outcome event (cardiovascular death, nonfatal type 1 myocardial infarction, or nonfatal ischemic stroke) occurred in 8.2 and 11.7 percent of patients in the polypill and usual-care groups, respectively (hazard ratio, 0.70). Patient-reported medication adherence was higher in the polypill group.\n<\/p>\n \n\t“By simplifying treatment complexity and improving availability, the use of a polypill is a widely applicable strategy to improve accessibility and adherence to treatment, thus decreasing the risk of recurrent disease and cardiovascular death,” the authors write.\n<\/p>\n \n\tSeveral authors disclosed financial ties to the pharmaceutical industry.\n<\/p>\n \n\tAbstract\/Full Text (subscription or payment may be required)<\/a>\n<\/p>\n \n\tEditorial (subscription or payment may be required)<\/a>\n<\/p>\n